Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5191653 | 0.90 | LOXL2 (0.51) | LOXL2CYP1A2NCF1HTR1AADRA1D | |
| SCHEMBL5205163 | 0.88 | LOXL2 (0.50) | LOXL2CYP1A2NCF1HTR1AADRA1D | |
| SCHEMBL8534353 | 0.88 | CYP19A1 (0.50) | LOXL2CYP1A2CYP3A4KDM4EALDH1A1 | |
| SCHEMBL3397178 | 0.81 | LOXL2 (0.58) | LOXL2CYP1A2NCF1HTR1AADRA1D | |
| SCHEMBL7747842 | 0.79 | LOXL2 (0.60) | LOXL2CYP1A2NCF1HTR1AADRA1D | |
| SCHEMBL6966651 | 0.79 | LOXL2 (0.60) | LOXL2CYP1A2NCF1HTR1AADRA1D | |
| SCHEMBL15453337 | 0.79 | NR4A2 (0.49) | CYP1A2KDM4EFLT1KDR | |
| SCHEMBL30045799 | 0.78 | CYP19A1 (0.48) | LOXL2CYP1A2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL28179223 | 0.78 | LOXL2 (0.50) | LOXL2CYP1A2NCF1HTR1AADRA1D | |
| SCHEMBL10133342 | 0.77 | LOXL2 (0.53) | LOXL2CYP1A2NCF1HTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140039171-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-06 | — | — | US | claimed |
| EP-2682399-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | Meiji Seika Pharma Co., Ltd. (JP) | 2014-01-08 | — | — | EP | claimed |
| CN-103391944-A | Novel macrolide intermediate and novel production process | MEIJI SEIKA PHARMA CO LTD | 2013-11-13 | — | — | CN | claimed |
| US-5939268-A | DIELS-ALDER REACTION PRODUCT OF A DIENE AND A DIENOPHILE; CHEMICAL INTERMEDIATES FOR DRUGS, SOLID PHASE SYNTHESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| EP-0773953-A1 | COMBINATORIAL LIBRARIES OF MOLECULES AND METHODS FOR PRODUCING SAME | THE SCRIPPS INSTITUTE (US) | 1997-05-21 | — | — | EP | claimed |
| WO-1996003424-A1 | COMBINATORIAL LIBRARIES OF MOLECULES AND METHODS FOR PRODUCING SAME | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-02-08 | — | — | WO | claimed |
| EP-2678349-B1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-9139609-B2 | C-4″ position substituted macrolide derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20140039171-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-06 | — | — | US | disclosed |
| EP-2682399-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | Meiji Seika Pharma Co., Ltd. (JP) | 2014-01-08 | — | — | EP | disclosed |
| EP-2678349-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-01-01 | — | — | EP | disclosed |
| CN-103492404-A | C-4' substituted macrolide derivatives | TAISHO PHARMACEUTICAL CO LTD | 2014-01-01 | — | — | CN | disclosed |
| US-5656607-A | Erythromycin derivatives | ROUSSEL UCLAF (FR) | 1997-08-12 | — | — | US | disclosed |
| EP-0773953-A1 | COMBINATORIAL LIBRARIES OF MOLECULES AND METHODS FOR PRODUCING SAME | THE SCRIPPS INSTITUTE (US) | 1997-05-21 | — | — | EP | disclosed |
| CN-1126997-A | Novel erythromycin derivatives, method for preparing same and use thereof as drugs | ROUSSEL UCLAF (FR) | 1996-07-17 | — | — | CN | disclosed |
| EP-0716093-A1 | Erythromycin derivatives, their process of preparation and application as medicaments | ROUSSEL UCLAF (FR) | 1996-06-12 | — | — | EP | disclosed |
| WO-1996003424-A1 | COMBINATORIAL LIBRARIES OF MOLECULES AND METHODS FOR PRODUCING SAME | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-02-08 | — | — | WO | disclosed |
| WO-1995027720-A1 | NOVEL ERYTHROMYCIN DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS DRUGS | ROUSSEL UCLAF (FR) | 1995-10-19 | — | — | WO | disclosed |
| EP-0676409-A1 | Erythromycin derivatives, their process for preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039171-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | MRPL21, PIGS, CYP51A1 | LOXL2 4157/4885CYP1A2 158/4885NCF1 2263/4885 |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MRPL21, MRPS34, MRPL37 | LOXL2 4859/4885CYP1A2 1987/4885NCF1 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.